Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxSelling, General & Administrative
Others
Ratios

Odyssey Health (ODYY) EBITDA (2016 - 2021)

Odyssey Health has reported EBITDA over the past 8 years, most recently at -$2.6 million for Q3 2021.

  • For Q3 2021, EBITDA fell 125.45% year-over-year to -$2.6 million; the TTM value through Jul 2021 reached -$15.9 million, down 312.32%, while the annual FY2025 figure was -$1.0 million, 52.29% up from the prior year.
  • EBITDA for Q3 2021 was -$2.6 million at Odyssey Health, up from -$12.1 million in the prior quarter.
  • Over five years, EBITDA peaked at -$26029.0 in Q1 2017 and troughed at -$23.4 million in Q3 2019.
  • A 5-year average of -$2.3 million and a median of -$231760.0 in 2018 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 28500.69% in 2019 and later surged 95.06% in 2020.
  • Year by year, EBITDA stood at -$49497.0 in 2017, then decreased by 5.87% to -$52404.0 in 2018, then crashed by 2424.08% to -$1.3 million in 2019, then surged by 60.29% to -$525269.0 in 2020, then crashed by 396.38% to -$2.6 million in 2021.
  • Business Quant data shows EBITDA for ODYY at -$2.6 million in Q3 2021, -$12.1 million in Q2 2021, and -$633792.0 in Q1 2021.